
Circassia appoints GSK’s Dr Brett Haumann
pharmafile | September 11, 2012 | Appointment | Business Services, Manufacturing and Production, Research and Development, Sales and Marketing | Brett Haumann, Circassia
Speciality biopharma firm Circassia has announced the appointment of Dr Brett Haumann as chief medical officer.
Haumann joins allergy-focussed Circassia from GlaxoSmithKline where he was vice president and Medicines Development leader, responsible for the late-stage development of once-daily inhaled medicines for the treatment of asthma and COPD.
“I am delighted Brett has chosen to join Circassia, where his extensive regulatory, medical and development experience will prove invaluable as we move our lead product into the final phase of clinical testing,” said Steve Harris, Circassia’s chief executive.
Haumann has over 15 years’ experience of pharma development gained at Glaxo Wellcome and GSK. During this time, he held a number of positions of increasing seniority, culminating in his most recent role as vice president, Medicines Development leader where he led a multifunctional team developing GSK’s next generation of inhaled respiratory products.
Related Content

Circassia terminates AstraZeneca partnership in exchange for £150m debt settlement
Circassia Pharmaceuticals has announced its decision to break away from a partnership it forged with …

Circassia stumbles with allergy treatments at clinical trial stage, again
Circassia has slumped at the Phase 2 clinical trial stage again, after its failure with …
Circassia raises funds to develop allergy products
UK biopharma company Circassia has raised £60 million funding for the final stage of development …






